MINNEAPOLIS--(BUSINESS WIRE)--Bright Health Group, Inc. (“Bright Health” or the “Company”) (NYSE: BHG), a diversified healthcare services company building a technology-enabled, fully-aligned, national Integrated System of Care personalized for consumers, today reported financial results for its fourth quarter and full year ended December 31, 2021.
“Bright Health Group achieved substantial growth in 2021, delivering $4 billion in Revenue, and reaching a significant scale milestone of serving over 1 million health plan lives for the start of 2022. While progressing on important foundational capabilities, this level of growth created challenges during the year which resulted in worse than expected performance,” said Mike Mikan, President and CEO of Bright Health Group. “Despite a challenging 2021, we have conviction in our strategy to continue driving alignment and integration of care delivery and financing at the local level. None of this is possible without an incredible team who deeply care about making healthcare right for consumers and we are focused on driving results off our scaled platform in 2022 and beyond.”
Key Metrics |
|||
|
As of December 31, |
||
|
2021 |
|
2020 |
Consumer and Patient Metrics |
|
|
|
Bright HealthCare Commercial Consumers |
611,078 |
|
145,459 |
Bright HealthCare Medicare Advantage Consumers |
116,621 |
|
61,663 |
NeueHealth Value-Based Patients |
175,587 |
|
21,126 |
|
Three Months Ended |
|
Twelve Months Ended |
||||||||||||
($ in thousands) |
December 31, |
|
December 31, |
||||||||||||
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
Financial Metrics |
|
|
|
|
|
|
|
||||||||
Revenue |
$ |
962,334 |
|
|
$ |
359,778 |
|
|
$ |
4,029,389 |
|
|
$ |
1,207,320 |
|
Medical Cost Ratio(1) |
|
134.1 |
% |
|
|
105.4 |
% |
|
|
101.3 |
% |
|
|
88.7 |
% |
Operating Cost Ratio |
|
47.7 |
% |
|
|
41.3 |
% |
|
|
30.7 |
% |
|
|
33.9 |
% |
GAAP Net Loss (2) |
$ |
(813,375 |
) |
|
$ |
(163,832 |
) |
|
$ |
(1,178,365 |
) |
|
$ |
(248,442 |
) |
Adjusted EBITDA (non-GAAP) (2) |
$ |
(790,149 |
) |
|
$ |
(157,724 |
) |
|
$ |
(1,080,906 |
) |
|
$ |
(238,912 |
) |
(1) |
Medical Cost Ratio for the three months ended December 31, 2021, includes a 860 basis point unfavorable impact from COVID-19 related costs and a 2,640 basis point unfavorable impact reflecting the combined impact of a cumulative reduction in Premium Revenue due to an inability to capture risk adjustment on newly added lives, as well as prior period medical costs recognized in the fourth quarter. This is compared to 2020, which included a 650 basis point unfavorable impact from COVID-19 costs and a 20 basis point unfavorable impact from non-COVID prior period developments (“PPD”). Medical Cost Ratio for the twelve months ended December 31, 2021, includes a 530 basis point unfavorable impact from COVID-19 costs, and a 90 basis point unfavorable impact from non-COVID PPD. This is compared to 2020, which included a 400 basis point unfavorable impact from COVID-19 costs, a 110 basis point favorable impact from non-COVID PPD, and a 110 basis point favorable impact due to deferred utilization. |
|
|
|
|
(2) |
GAAP Net Loss and Adjusted EBITDA (non-GAAP) include $102.8 million of premium deficiency reserve related to expected future losses in certain states in 2022. |
See the table at the end of this release for additional information and a reconciliation of the non-GAAP measure used in the table above.
Financial Outlook
For full year 2022, Bright Health Group is providing the following guidance and commentary:
- Bright Health Group’s total Revenue is expected to be $6.8 billion to $7.1 billion with an expected enterprise Medical Cost Ratio between 90% and 94%.
- On a segment basis, Bright HealthCare end-of-year membership is expected to be approximately 1,000,000, while NeueHealth Revenue is expected to be approximately $2.3 billion.
- Intercompany Revenue elimination, comprised of payments from Bright HealthCare to NeueHealth for managing patient care and for network services, is expected to be approximately $1.2 to $1.4 billion.
- Adjusted EBITDA for 2022 is expected to be a loss of between $500.0 and $800.0 million†.
Earnings Conference Call
As previously announced, Bright Health Group will discuss the Company’s results, strategy, and outlook on a conference call with investors at 8:00 a.m. Eastern Time today. Bright Health Group will host a live webcast of this conference call which can be accessed from the Investor Relations page of the company’s website (investors.brighthealthgroup.com). Following the call, a webcast replay will be available on the same site. This earnings release and the Form 8-K dated March 2, 2022, can be accessed on the Investor Relations page of the Company’s website. We routinely post important information on our website, including corporate and investor presentations and financial information. We intend to use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included in the Investor Relations section of our website. Accordingly, investors should monitor this portion of our website, in addition to following our press releases, Securities and Exchange filings and public conference calls and webcasts.
About Bright Health Group
Bright Health Group is the first technology-enabled, fully-aligned system of care built for healthcare's consumer retail market. Our differentiated approach aligns care delivery with the financing of care to drive better outcomes, lower costs, and enhance the consumer experience. We have two market-facing businesses: NeueHealth and Bright HealthCare. NeueHealth provides care delivery and value-based enablement services to over 400,000 value-based patients through our owned and affiliated clinics. Bright HealthCare offers Commercial and Medicare health plan products to over one million consumers across the nation. We believe everyone should have access to personal, affordable, and high-quality healthcare. Our mission is to Make healthcare right. Together. For more information, visit www.brighthealthgroup.com.
Notes
† A reconciliation of the projected Adjusted EBITDA, which is a forward-looking non-GAAP financial measure, to the most directly comparable GAAP financial measures, is not provided because the Company is unable to provide such reconciliation without unreasonable effort. The inability to provide a reconciliation is due to the uncertainty and inherent difficulty predicting the occurrence, the financial impact and the periods in which the non-GAAP adjustments may be recognized. These GAAP measures may include the impact of such items as interest expense, income tax expense, depreciation and amortization, share-based compensation expense; transaction costs, changes in the fair value of contingent consideration, contract termination costs; and the tax effect of all such items. Historically, the Company has excluded these items from non-GAAP financial measures. The Company currently expects to continue to exclude these items in future disclosures of non-GAAP financial measures and may also exclude other items that may arise (collectively, “non-GAAP adjustments”). The decisions and events that typically lead to the recognition of non-GAAP adjustments, such as a decision to exit part of the business, are inherently unpredictable as to if or when they may occur. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.
Forward-Looking Statements
Statements made in this release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as “anticipate,” “expect,” “plan,” “believe,” “intend,” “project,” “forecast,” “estimates,” “projections,” and other similar expressions. These forward-looking statements include any statements regarding our plans and expectations with respect to Bright Health Group, Inc. Such forward-looking statements are subject to various risks, uncertainties and assumptions. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Factors that might materially affect such forward-looking statements include: a lack of acceptance or slow adoption of our business model; our ability to retain existing consumers and expand consumer enrollment; our ability to accurately assess, code and report IFP and MA risk adjustment factor scores for our consumers; our ability to contract with care providers and arrange for the provision of quality care; our ability to accurately estimate our medical expenses, effectively manage our costs and claims liabilities or appropriately price our products and charge premiums; the impact of the ongoing COVID-19 pandemic on our business and results of operations; the risks associated with our reliance on third-party providers to operate our business; the impact of modifications or changes to the U.S. health insurance markets; our ability to manage the growth of our business; our ability to operate, update or implement our technology platform and other information technology systems; our ability to retain key executives; our ability to successfully pursue acquisitions and integrate acquired businesses; the occurrence of severe weather events, catastrophic health events, natural or man-made disasters, and social and political conditions or civil unrest; our ability to prevent and contain data security incidents and the impact of data security incidents on our members, patients, employees and financial results; our ability to comply with requirements to maintain effective internal controls; and the other factors set forth under the heading “Risk Factors” in Bright Health Group’s prospectus filed pursuant to Rule 424(b)(4) on June 25, 2021, and our other filings with the U.S. Securities and Exchange Commission. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this release to conform these statements to actual results or changes in our expectations.
Bright Health Group, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (in thousands, except share and per share data) (Unaudited) |
|||||||
|
December 31,
|
|
December 31,
|
||||
Assets |
|
|
|
||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
1,061,179 |
|
|
$ |
488,371 |
|
Short-term investments |
|
193,835 |
|
|
|
499,928 |
|
Accounts receivable, net of allowance of $4,074 and $2,602, respectively |
|
113,474 |
|
|
|
60,522 |
|
Prepaids and other current assets |
|
291,712 |
|
|
|
130,986 |
|
Total current assets |
|
1,660,200 |
|
|
|
1,179,807 |
|
Other assets: |
|
|
|
||||
Long-term investments |
|
675,192 |
|
|
|
175,176 |
|
Property, equipment and capitalized software, net |
|
38,344 |
|
|
|
12,264 |
|
Goodwill |
|
835,140 |
|
|
|
263,035 |
|
Intangible assets, net |
|
343,860 |
|
|
|
152,211 |
|
Other non-current assets |
|
45,603 |
|
|
|
28,309 |
|
Total other assets |
|
1,938,139 |
|
|
|
630,995 |
|
Total assets |
$ |
3,598,339 |
|
|
$ |
1,810,802 |
|
Liabilities, Redeemable Noncontrolling Interest, Redeemable Preferred Stock and Shareholders’ Equity (Deficit) |
|
|
|
||||
Current liabilities: |
|
|
|
||||
Medical costs payable |
$ |
817,975 |
|
|
$ |
249,777 |
|
Accounts payable |
|
118,140 |
|
|
|
57,252 |
|
Unearned revenue |
|
53,295 |
|
|
|
34,628 |
|
Risk adjustment payable |
|
931,170 |
|
|
|
187,777 |
|
Short-term borrowings |
|
155,000 |
|
|
|
— |
|
Other current liabilities |
|
207,238 |
|
|
|
35,847 |
|
Total current liabilities |
|
2,282,818 |
|
|
|
565,281 |
|
Other liabilities |
|
41,994 |
|
|
|
28,578 |
|
Total liabilities |
|
2,324,812 |
|
|
|
593,859 |
|
Redeemable noncontrolling interests |
|
128,407 |
|
|
|
39,600 |
|
Redeemable preferred stock, $0.0001 par value; 100,000,000 and 166,307,087 shares authorized in 2021 and 2020, respectively; — and 164,244,893 shares issued and outstanding in 2021 and 2020, respectively |
|
— |
|
|
|
1,681,015 |
|
Shareholders’ equity (deficit): |
|
|
|
||||
Common stock, $0.0001 par value; 3,000,000,000 and 658,993,725 shares authorized in 2021 and 2020, respectively; 628,622,872 and 137,662,698 shares issued and outstanding in 2021 and 2020, respectively |
|
63 |
|
|
|
14 |
|
Additional paid-in capital |
|
2,861,243 |
|
|
|
9,877 |
|
Accumulated deficit |
|
(1,700,851 |
) |
|
|
(515,989 |
) |
Accumulated other comprehensive (loss) income |
|
(3,335 |
) |
|
|
2,426 |
|
Treasury stock, at cost, 2,522,148 and — shares at December 31, 2021 and 2020, respectively |
|
(12,000 |
) |
|
|
— |
|
Total shareholders’ equity (deficit) |
|
1,145,120 |
|
|
|
(503,672 |
) |
Total liabilities, redeemable noncontrolling interests, redeemable preferred stock and shareholders’ equity (deficit) |
$ |
3,598,339 |
|
|
$ |
1,810,802 |
|
Bright Health Group, Inc. and Subsidiaries Condensed Consolidated Statements of Income (Loss) (in thousands, except share and per share data) (Unaudited) |
|||||||||||||||
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
||||||||||||
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
Revenue: |
|
|
|
|
|
|
|
||||||||
Premium revenue |
$ |
979,764 |
|
|
$ |
353,203 |
|
|
$ |
3,902,714 |
|
|
$ |
1,180,338 |
|
Service revenue |
|
11,099 |
|
|
|
5,170 |
|
|
|
42,701 |
|
|
|
18,514 |
|
Investment income |
|
(28,529 |
) |
|
|
1,405 |
|
|
|
83,974 |
|
|
|
8,468 |
|
Total revenue |
|
962,334 |
|
|
|
359,778 |
|
|
|
4,029,389 |
|
|
|
1,207,320 |
|
Operating expenses: |
|
|
|
|
|
— |
|
|
|
— |
|
||||
Medical costs |
|
1,313,531 |
|
|
|
372,186 |
|
|
|
3,953,674 |
|
|
|
1,047,300 |
|
Operating costs |
|
459,297 |
|
|
|
148,684 |
|
|
|
1,238,387 |
|
|
|
409,334 |
|
Depreciation and amortization |
|
9,503 |
|
|
|
2,739 |
|
|
|
35,484 |
|
|
|
8,289 |
|
Total operating expenses |
|
1,782,331 |
|
|
|
523,609 |
|
|
|
5,227,545 |
|
|
|
1,464,923 |
|
Operating loss |
|
(819,997 |
) |
|
|
(163,831 |
) |
|
|
(1,198,156 |
) |
|
|
(257,603 |
) |
Interest expense |
|
1,674 |
|
|
|
— |
|
|
|
7,956 |
|
|
|
— |
|
Other income |
|
— |
|
— |
|
— |
|
— |
|
(1,226 |
) |
— |
|
— |
|
Loss before income taxes |
|
(821,671 |
) |
|
|
(163,831 |
) |
|
|
(1,204,886 |
) |
|
|
(257,603 |
) |
Income tax (benefit) expense |
|
(8,296 |
) |
|
|
1 |
|
|
|
(26,521 |
) |
|
|
(9,161 |
) |
Net loss |
|
(813,375 |
) |
|
|
(163,832 |
) |
|
|
(1,178,365 |
) |
|
|
(248,442 |
) |
Net earnings attributable to noncontrolling interests |
|
(1,143 |
) |
|
|
— |
|
|
|
(6,497 |
) |
|
|
— |
|
Net loss attributable to Bright Health Group, Inc. common shareholders |
$ |
(814,518 |
) |
|
$ |
(163,832 |
) |
|
$ |
(1,184,862 |
) |
|
$ |
(248,442 |
) |
Basic and diluted loss per share attributable to Bright Health Group, Inc. common shareholders |
$ |
(1.29 |
) |
|
$ |
(1.20 |
) |
|
$ |
(3.02 |
) |
|
$ |
(1.82 |
) |
Basic and diluted weighted-average common shares outstanding |
|
629,485 |
|
|
|
136,968 |
|
|
|
392,243 |
|
|
|
136,193 |
|
Bright Health Group, Inc. and Subsidiaries Condensed Consolidated Statements of Cash Flows (in thousands) (Unaudited) |
|||||||
|
Twelve Months Ended December 31, |
||||||
|
|
2021 |
|
|
|
2020 |
|
Cash flows from operating activities: |
|
|
|
||||
Net loss |
$ |
(1,184,862 |
) |
|
$ |
(248,442 |
) |
Adjustments to reconcile net loss to net cash provided by operating activities: |
|
|
|
||||
Depreciation and amortization |
|
35,484 |
|
|
|
8,289 |
|
Share-based compensation |
|
68,423 |
|
|
|
5,452 |
|
Deferred income taxes |
|
(25,654 |
) |
|
|
— |
|
Unrealized gains on equity securities |
|
(80,231 |
) |
|
|
— |
|
Other, net |
|
20,254 |
|
|
|
2,667 |
|
Changes in assets and liabilities, net of acquired assets and liabilities: |
|
|
|
||||
Accounts receivable |
|
(32,941 |
) |
|
|
24,631 |
|
Other assets |
|
(143,463 |
) |
|
|
(44,061 |
) |
Medical cost payable |
|
475,461 |
|
|
|
78,591 |
|
Risk adjustment payable |
|
742,075 |
|
|
|
100,974 |
|
Accounts payable and other liabilities |
|
192,611 |
|
|
|
(3,962 |
) |
Unearned revenue |
|
14,902 |
|
|
|
18,623 |
|
Net cash provided by (used in) operating activities |
|
82,059 |
|
|
|
(57,238 |
) |
Cash flows from investing activities: |
|
|
|
||||
Purchases of investments |
|
(1,017,588 |
) |
|
|
(916,823 |
) |
Proceeds from sales, paydown, and maturities of investments |
|
926,901 |
|
|
|
463,887 |
|
Purchases of property and equipment |
|
(30,414 |
) |
|
|
(6,474 |
) |
Business acquisitions, net of cash acquired |
|
(431,791 |
) |
|
|
(230,332 |
) |
Net cash used in investing activities |
|
(552,892 |
) |
|
|
(689,742 |
) |
Cash flows from financing activities: |
|
|
|
||||
Proceeds from issuance of preferred stock |
|
— |
|
|
|
711,200 |
|
Proceeds from issuance of common stock |
|
11,390 |
|
|
|
1,241 |
|
Net proceeds from short-term borrowings |
|
155,000 |
|
|
|
— |
|
Payments for debt issuance costs |
|
(3,391 |
) |
|
|
— |
|
Proceeds from IPO |
|
887,328 |
|
|
|
— |
|
Payments for IPO offering costs |
|
(6,686 |
) |
|
|
— |
|
Net cash provided by financing activities |
|
1,043,641 |
|
|
|
712,441 |
|
Net increase (decrease) in cash and cash equivalents |
|
572,808 |
|
|
|
(34,539 |
) |
Cash and cash equivalents – beginning of year |
|
488,371 |
|
|
|
522,910 |
|
Cash and cash equivalents – end of year |
$ |
1,061,179 |
|
|
$ |
488,371 |
|
Bright Health Group, Inc. and Subsidiaries Segment Information (in thousands) (Unaudited) |
|||||||||||||||
Bright HealthCare |
Three Months Ended |
|
Twelve Months Ended |
||||||||||||
(in thousands) |
December 31, |
|
December 31, |
||||||||||||
Statements of income (loss) and operating data: |
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
|
|
|
|
|
|
|
|
||||||||
Bright HealthCare: |
|
|
|
|
|
|
|
||||||||
Revenue: |
|
|
|
|
|
|
|
||||||||
Commercial premium revenue |
$ |
581,699 |
|
|
$ |
181,518 |
|
|
$ |
2,512,624 |
|
|
$ |
692,433 |
|
Medicare Advantage premium revenue |
|
367,899 |
|
|
|
169,842 |
|
|
|
1,297,273 |
|
|
|
480,112 |
|
Investment income |
|
248 |
|
|
|
1,405 |
|
|
|
3,739 |
|
|
|
8,468 |
|
Total revenue |
|
949,846 |
|
|
|
352,765 |
|
|
|
3,813,636 |
|
|
|
1,181,013 |
|
Operating expenses |
|
|
|
|
|
|
|
— |
|
||||||
Medical costs |
|
1,178,701 |
|
|
|
372,186 |
|
|
|
3,766,897 |
|
|
|
1,047,300 |
|
Operating costs |
|
433,322 |
|
|
|
138,785 |
|
|
|
1,140,842 |
|
|
|
376,215 |
|
Depreciation and amortization |
|
5,544 |
|
|
|
2,263 |
|
|
|
17,068 |
|
|
|
6,394 |
|
Total operating expenses |
|
1,617,567 |
|
|
|
513,234 |
|
|
|
4,924,807 |
|
|
|
1,429,909 |
|
Operating loss |
$ |
(667,721 |
) |
|
$ |
(160,469 |
) |
|
$ |
(1,111,171 |
) |
|
$ |
(248,896 |
) |
|
|
|
|
|
|
|
|
||||||||
Medical Cost Ratio (MCR) |
|
124.1 |
% |
|
|
105.9 |
% |
|
|
98.9 |
% |
|
|
89.3 |
% |
NeueHealth |
Three Months Ended |
|
Twelve Months Ended |
||||||||||||
($ in thousands) |
December 31, |
|
December 31, |
||||||||||||
Statements of income (loss) data: |
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
|
|
|
|
|
|
|
|
||||||||
NeueHealth: |
|
|
|
|
|
|
|
||||||||
Revenue: |
|
|
|
|
|
|
|
||||||||
Premium revenue |
$ |
116,418 |
|
|
$ |
1,843 |
|
|
$ |
338,254 |
|
|
$ |
7,793 |
|
Service revenue |
|
19,881 |
|
|
|
7,834 |
|
|
|
74,690 |
|
|
|
29,354 |
|
Investment income |
|
(28,777 |
) |
|
|
— |
|
|
|
80,235 |
|
|
|
— |
|
Total revenue |
|
107,522 |
|
|
|
9,677 |
|
|
|
493,179 |
|
|
|
37,147 |
|
Operating expenses: |
|
|
|
|
|
— |
|
|
|
— |
|
||||
Medical costs |
|
221,142 |
|
|
|
— |
|
|
|
432,318 |
|
|
|
— |
|
Operating costs |
|
34,697 |
|
|
|
12,563 |
|
|
|
129,430 |
|
|
|
43,959 |
|
Depreciation and amortization |
|
3,959 |
|
|
|
476 |
|
|
|
18,416 |
|
|
|
1,895 |
|
Total operating expenses |
|
259,798 |
|
|
|
13,039 |
|
|
|
580,164 |
|
|
|
45,854 |
|
Operating loss |
$ |
(152,276 |
) |
|
$ |
(3,362 |
) |
|
$ |
(86,985 |
) |
|
$ |
(8,707 |
) |
|
|
|
|
|
|
|
|
||||||||
Medical Cost Ratio (MCR) |
|
190.0 |
% |
|
|
— |
% |
|
|
127.8 |
% |
|
|
— |
% |
Non-GAAP Financial Measures
We use the non-GAAP financial measure Adjusted EBITDA. We define Adjusted EBITDA as Net Loss excluding Interest Expense, Income Taxes, Depreciation and Amortization, adjusted for the impact of acquisition and financing-related transaction costs, share-based compensation and changes in the fair value of contingent consideration. This non-GAAP measure has been presented in this quarterly Earnings Release as a supplemental measure of financial performance that is not required by or presented in accordance with GAAP because we believe it assists management and investors in comparing our operating performance across reporting periods on a consistent basis by excluding and including items that we do not believe are indicative of our core operating performance. Management believes this measure is useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses Adjusted EBITDA to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation and to compare our performance against that of other peer companies using similar measures. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone.
Adjusted EBITDA is not a recognized term under GAAP and should not be considered as an alternative to Net Income (Loss) as a measure of financial performance or any other performance measure derived in accordance with GAAP. Additionally, Adjusted EBITDA is not intended to be a measure of free cash flow available for management’s discretionary use as it does not consider certain cash requirements such as interest payments, tax payments and debt service requirements. The presentation of Adjusted EBITDA has limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentation of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.
The following table provides a reconciliation of net loss to Adjusted EBITDA for the periods presented:
|
Three Months Ended
|
|
Twelve Months Ended
|
||||||||||||
($ in thousands) |
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
Net loss |
$ |
(813,375 |
) |
|
$ |
(163,832 |
) |
|
$ |
(1,178,365 |
) |
|
$ |
(248,442 |
) |
Interest expense |
|
1,674 |
|
|
|
— |
|
|
|
7,956 |
|
|
|
— |
|
Income tax (benefit) expense |
|
(8,296 |
) |
|
|
1 |
|
|
|
(26,521 |
) |
|
|
(9,161 |
) |
Depreciation and amortization |
|
9,503 |
|
|
|
2,739 |
|
|
|
35,484 |
|
|
|
8,289 |
|
Transaction costs (a) |
|
740 |
|
|
|
1,638 |
|
|
|
6,338 |
|
|
|
4,950 |
|
Share-based compensation expense (b) |
|
25,189 |
|
|
|
1,730 |
|
|
|
68,423 |
|
|
|
5,452 |
|
Change in fair value of contingent consideration (c) |
|
(5,584 |
) |
|
|
— |
|
|
|
(4,221 |
) |
|
|
— |
|
Contract termination costs (d) |
|
— |
|
|
|
— |
|
|
|
10,000 |
|
|
|
— |
|
Adjusted EBITDA |
$ |
(790,149 |
) |
|
$ |
(157,724 |
) |
|
$ |
(1,080,906 |
) |
|
$ |
(238,912 |
) |
(a) |
Transaction costs include accounting, tax, valuation, consulting, legal and investment banking fees directly relating to business combinations and certain costs associated with our initial public offering. These costs can vary from period to period and impact comparability, and we do not believe such transaction costs reflect the ongoing performance of our business. |
|
(b) |
Represents non-cash compensation expense related to stock option and restricted stock award grants, which can vary from period to period based on a number of factors, including the timing, quantity and grant date fair value of the awards. |
|
(c) |
Represents the non-cash change in fair value of contingent consideration from business combinations, which is remeasured at fair value each reporting period. There was no material activity for periods prior to the first quarter of 2021. |
|
(d) |
Represents amount paid for early termination of an existing vendor contract. |
